Duality Biotherapeutics reports DB-1303 Phase 3 trial meets primary PFS endpoint

Reuters03-23
Duality Biotherapeutics reports DB-1303 Phase 3 trial meets primary PFS endpoint
  • Duality reported progress across its antibody-drug conjugate portfolio, including 10 clinical-stage programs that have enrolled more than 3,200 patients globally.
  • In breast cancer, the company said DB-1303 met a primary endpoint in a Phase 3 study versus T-DM1, supporting a potential path toward expanded use in later-line HER2+ disease.
  • For prostate cancer, updated DB-1311 data in 146 heavily pretreated mCRPC patients showed a median rPFS of 11.3 months and a median OS of 22.5 months, positioning the asset for a planned global Phase 3 trial starting in 2026.
  • In lung and breast cancer settings, Duality said DB-1310 received two FDA fast track designations, which could shorten development timelines and broaden partnering options.
  • The company also said DB-1324 received FDA IND clearance and has entered a global Phase 1/2 study, extending its pipeline into gastrointestinal tumor indications.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Duality Biotherapeutics Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260323-12063553), on March 23, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment